International Paper Company Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? International Paper Company Common Stock trades at $32.09 (market cap $16.85B), while Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and International Paper Company Common Stock pays a 5.82% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Paper Company Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| IP | ROIV | |
|---|---|---|
Market Cap | $16.85B | $24.99B |
Volume | 3,482,586 | 4,711,562 |
Sector | Basic Materials | Health |
52-Week High | $49.19 | $41.81 |
52-Week Low | $29.38 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $25.81B | $21.25B |
Dividend Yield | 5.82% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
International Paper Company is a US producer of fiber-based packaging, pulp, and paper products, manufacturing corrugated packaging and containerboard used to ship and protect goods.
Read more on IP →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →